Chronic lymphocytic leukaemia

BGB-16673

BGB-16673, a Bruton's tyrosine kinase (BTK) degrader, uses proteolysis targeting chimera (PROTAC) technology to selectively degrade both wild-type and mutant forms of BTK, a key enzyme involved in B-cell development and signalling.[71]Sabakhtarishvili G, Alshebli M, Bajwa O, et al. Bruton tyrosine kinase degraders: current concepts. Am J Clin Oncol. 2025 Feb 14. http://www.ncbi.nlm.nih.gov/pubmed/39950399?tool=bestpractice.com ​ A phase 3 open-label randomised study is currently ongoing to evaluate the efficacy and safety of BGB-16673 compared with standard care (investigators choice of idelalisib plus rituximab, or bendamustine plus rituximab, or venetoclax plus rituximab retreatment) in patients with previously treated (BTK inhibitor and B-cell lymphoma-2 protein [BCL2] inhibitor) chronic lymphocytic leukaemia.[72]ClinicalTrials.gov. A study of BGB-16673 compared to investigator's choice in participants with chronic lymphocytic leukemia previously exposed to both Bruton tyrosine kinase (BTK) and B-cell leukemia/​lymphoma 2 protein (BCL2) inhibitors. Mar 2025 [internet publication]. https://clinicaltrials.gov/study/NCT06846671